Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happy July 4th to all! Solid week of accumulation.
Enjoy the family!
3
Wink-wink
Wouldn’t that be nice!!
Nice climb up for the day and good way to end the week. Remains good level to accumulate more!
Nice way to end the week!
Quiet board….good sign of soft and quiet accumulation.
Agree 100% Penny!
Excellent
Now that is funny!!
Hi everyone! Does anyone have a perspective on the timeline for funding and when companies find out if they received any monies?
TIA
3
News release won’t copy and paste but solid news today
Expected FDA approval for KEYARX(TM) (racemic ketamine) via the a ANDA pathway in Q1, 2024 and commercial launch in queue to 2024
Bout time!
No gap today. Friday closed at .0456 todays low is .045
So true!
Ty….keep us posted if you do get line with CEO. Rail has tons of opportunity. Highways, heat, high gas, etc. afford railway as solid transport options. If share structure isn’t diluted we should have solid upswing.
GLTY
~3
Very nice article.
GEGI has a strong management team behind it led by CEO Kevin Damoa, a Space X executive who previously held leadership positions at Northrop Grumann and the EV automaker Canoo. Mr. Damoa was appointed by Braden Jones who became the new controlling shareholder of GEGI when he was issued 1,000 shares of Series A Preferred stock giving him 51% of the total voting power of the Company’s common shareholders. This was followed by a debt restructuring and the resolution of a dispute with a former debtor. Since then, GEGI has been beefing up its BOD bringing on autonomous EV industry veteran Kasey Evans who is a board member at Einride, trading at a $1.2 billion market valuation. They also brought on Jack Hedge as a Strategic Advisor. Mr. Hedge was previously President of the Utah Inland Port Authority and director of cargo for the Port of Los Angeles where he led the development, leasing, and asset management functions of the largest container port complex in North America, managing a $4 billion portfolio and more than $270 billion in cargo annually. Mr. Hedge’s contacts and connections within the transportation industry are second to none.
Agree, solid close….especially considering overall market trend for the day. Looking forward to next week!
Good morning! How “real-time” iate share structure updates posted?
TIA
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
WAKEFIELD, MA / June 21, 2023 Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the United States Patent and Trade Office (USPTO), on June 6, 2023, granted a patent, “Host Defense Protein (HDP) Mimetics for Prophylaxis and/or Treatment of Inflammatory Diseases of the Gastrointestinal Tract,” and also recently issued a Notice of Allowance for the patent application, “Arylamide Compounds For Treatment Of Viral Infections.”
These allowed patents, which encompass Brilacidin protections through 2036 and 2041, respectively, further strengthen Brilacidin intellectual property rights previously granted in the U.S. and other regions. Brilacidin is a Host Defense Protein-mimetic drug candidate with broad-spectrum immunomodulatory and antimicrobial properties.
Related to the claims of these newly allowed patents, Brilacidin has been tested in Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) (by rectal enema administration), where most patients achieved clinical remission, with further progress made in the development of an oral Brilacidin formulation for treatment of Ulcerative Colitis and Crohn’s Disease. The Company out-licensed Brilacidin in UP/UPS to Alfasigma S.p.A. Brilacidin has also been evaluated in Phase 2 testing in moderate-to-severe hospitalized cases of COVID-19 (by intravenous delivery), with beneficial treatment effects observed in patient subgroups. Biomarker-based trial design (enrollment tied to specific subgroups) has been highlighted by Biomedical Advanced Research and Development Authority (BARDA) scientists as a critical step to increase the likelihood of achieving clinical efficacy of investigational drugs in COVID-19 and Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS).
A separate patent application has been submitted to the USPTO for use of Brilacidin in fungal diseases. Encouraging Brilacidin pre-clinical results (in vitro and in vivo) against multiple fungal infections have been achieved, as recently published in an article in Nature Communications, and based on in vitro screening studies conducted by independent researchers. Additional in vivo testing in efficacy models against two hard-to-treat fungal pathogens is scheduled for 3Q2023.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, and infectious diseases. The Company is also active in evaluating other potential investment opportunities that can add value and diversify its portfolio.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements concerning future product development plans, including with respect to specific indications; statements regarding the therapeutic potential and capabilities of the StingRay System; future regulatory developments; and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are risks related to conducting pre-clinical studies and clinical trials and seeking regulatory and licensing approvals in the United States and other jurisdictions, including without limitation that compounds and devices may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere; prior test results may not be replicated in future studies and trials; the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development, including the amount and timing of the sale of shares of common stock under securities purchase agreements; and the Company’s licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments. A more complete description of these and other risk factors is included in the Company’s filings with the Securities and Exchange Commission. Many of these risks, uncertainties and assumptions are beyond the Company’s ability to control or predict. You should not place undue reliance on any forward-looking statements. The forward-looking statements speak only as of the information currently available to the Company on the date they are made, and the Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Patent approval news out
BigTime Penny Stocks: Genesis Electronics (GEGI) is Leading the Autonomous Freight Era
June 14, 2023 at 04:00 am
GENESIS ELECTRONICS GROUP, INC.
0.003400 USD -2.86%
Introducing Genesis Electronics Group, Inc. (OTC: GEGI), a game-changer in the transportation industry. Through its subsidiary, Glid, the company is pioneering the development of cutting-edge autonomous road-to-rail shipping vehicles known as Gliders. With a commitment to delivering a greener and more sustainable future, Genesis Electronics Group offers a unique "Glider-as-a-Service" business model. Recent milestones, including strategic investments, exclusive manufacturing partnerships, and groundbreaking rail inspection technology, demonstrate the company's dedication to revolutionizing the intermodal transportation landscape. As Genesis Electronics Group sets its sights on the thriving U.S. freight rail market, it aims to tap into its massive potential for innovation and improvement. With a rapidly expanding market worth over $70 billion and a compound annual growth rate exceeding 4%, the U.S. freight rail industry offers unparalleled opportunities for Genesis Electronics Group to lead the industry's transformation and meet the evolving needs of rail operators, customers, and regulators. Get ready to embark on a journey of innovation and progress with Genesis Electronics Group and witness the future of intermodal transportation unfold.
Genesis Electronics Group, Inc, is in the process of constructing cutting-edge autonomous road-to-rail shipping vehicles known as Gliders. These innovative vehicles will facilitate the transportation of fully loaded semi-trailers onto railway tracks, even in scenarios where it was previously deemed impractical. Genesis Electronics Group intends to possess and operate every Glider within its fleet, while also offering a business model referred to as "Glider-as-a-Service."
On May 4, 2023, Genesis Electronics Group, Inc. made an announcement regarding the completion of its current Reg A offering with the final subscription agreement for $190,000 from Strategic Investor, 40 Brightwater, LLC. As per Rule 144, these shares will be subject to restrictions due to the size of the investment.
Kevin Damoa, the CEO of Genesis Electronics Group, expressed appreciation for Shannon Newby and 40 Brightwater LLC's investment, emphasizing its significance for both their Glid technology and the nation's commitment to swiftly transitioning towards a greener and more sustainable future. The company is grateful for the belief and support received and eagerly anticipates collaborating to forge a brighter tomorrow in intermodal transportation.
Also, on May 26, 2023, Genesis Electronics Group, Inc. (GEGI) announced the execution of loan agreements for a credit facility with 40 Brightwater, LLC, allowing GEGI to borrow up to $750,000. The loan is expected to be finalized and funded by June 15, 2023.
Following their initial investment in GEGI through the Company's Reg A offering, 40 Brightwater, LLC has demonstrated growing interest in GEGI's business, technology, management team, and business potential. They are now providing this credit facility to support GEGI's operations and the development of its initial Glider units.
The proposed loan is part of a larger financial arrangement between Clear Rock Sustainable Energy, Inc. (Clear Rock Energy) and 40 Brightwater, LLC. This arrangement aims to establish an expanded business relationship between Genesis Electronics Group and Clear Rock Energy, focusing on GEGI's Glid autonomous road-to-rail patent-pending shipping technology. The collaboration seeks to explore new business opportunities in Mexico, Nigeria, South Africa, and Zimbabwe, where Clear Rock Energy has subsidiaries and business relationships. The ultimate goal is to secure new global markets for Genesis Electronics Group's Gliders.
On June 06, 2023, Genesis Electronics Group, Inc. (GEGI) unveiled its cutting-edge rail inspection and safety testing technology for Glider units. This advanced feature enables the transmission of crucial safety data to operators and railroad owners. Each unit pair will be equipped with rail inspection capabilities, utilizing Non-Destructive Evaluation/Test (NDE/T) technology to detect rail defects and assess track conditions. The system includes high-quality point-tilt-zoom (PTZ) cameras and 3DLOC software, enabling the Glider to geotag inspection data and seamlessly upload it to Glid's database. This comprehensive service, known as GLaaS (Glider-as-a-Service), provides detailed reports to customers and rail owners, facilitating more precise and efficient outage planning, reducing downtime, and minimizing revenue loss.
According to the Federal Railroad Administration, track failures caused 783 train derailments between 2018 and 2021, resulting in 14 fatalities and direct costs exceeding $165 million. These figures do not account for indirect costs to communities or revenue losses due to unusable lines.
Genesis Electronics Group has garnered significant praise and interest from short-track rail owners, who see the potential of integrating Glid units for track inspections during freight transportation. The company plans to incorporate this groundbreaking technology into its initial Beta units.
Also, on June 12, 2023, Genesis Electronics Group, Inc. (GEGI) announced the signing of an exclusive manufacturing partnership agreement with Bart Manufacturing, Inc. This collaboration will focus on building Glid units.
Glid and Bart have confirmed that production of the all-electric Glid units is scheduled to commence at the end of summer. The final joint design for manufacturing activities will be completed at Bart's state-of-the-art facility in Stockton, CA. Bart has a strong track record of providing engineering solutions to various industries such as Technology, Automotive, Aerospace, Industrial Systems, Consumer Electronics, and Solar.
Kevin Damoa, CEO of GEGI and Glid, emphasized the shared commitment to delivering a high-quality product that addresses the pressing need for a decarbonized and safer solution for short line rail operators across the United States.
This broad and comprehensive agreement encompasses planned volumes, manufacturing costs, and quality metrics necessary to achieve the company's initial milestone of completing the first 10 sets of Beta units. These units will be deployed in the field to validate the product's durability, reliability, and quality. The insights gained from the Beta Program will inform Glid and Bart's commercialization program throughout 2029, encompassing all stages, including crucial planning and launch phases.
By targeting U.S. freight railroads, companies like Genesis Electronics Group can tap into a vast market with significant potential for innovation and improvement. The implementation of advanced technologies, such as Glid units, can greatly enhance the safety, efficiency, and environmental performance of freight rail operations. This, in turn, can lead to substantial cost savings for rail operators and contribute to a more sustainable and resilient logistics ecosystem.
Moreover, the U.S. freight rail industry is subject to evolving regulatory standards and requirements. As the industry moves toward decarbonization and increased focus on safety, companies that provide innovative solutions tailored to meet these evolving demands stand to gain a competitive advantage. By targeting the U.S. freight railroads, Genesis Electronics Group can position itself as a key player in driving the industry's transformation and meeting the evolving needs of rail operators, customers, and regulators.
To add, the U.S. freight rail industry represents a substantial market with significant growth potential. According to market research reports, the U.S. freight rail market was valued at over $70 billion in recent years. This figure is expected to witness robust growth in the coming years, driven by various factors such as increasing demand for efficient transportation, expanding e-commerce activities, and the need for sustainable logistics solutions. The market's compound annual growth rate (CAGR) has been impressive, consistently exceeding 4% over the past few years. This indicates a rapid expansion of the industry year by year. The U.S. freight rail market offers immense opportunities for companies that can introduce innovative technologies and solutions to enhance operational efficiency, safety, and sustainability in this evolving landscape.
In conclusion, Genesis Electronics Group, Inc. (OTC: GEGI) is spearheading a transformative shift in the transportation industry through its cutting-edge Glid autonomous road-to-rail shipping vehicles. By forging strategic partnerships, implementing advanced rail inspection technology, and focusing on the U.S. freight rail market, the company is poised to drive innovation, sustainability, and operational excellence. With a substantial market size and a robust growth trajectory, the U.S. freight rail industry presents significant opportunities for Genesis Electronics Group to introduce state-of-the-art solutions and shape the future of intermodal transportation. The company's commitment to delivering high-quality, greener, and safer transportation solutions positions it as a key player in driving industry transformation and meeting evolving market demands. Witness the remarkable journey of Genesis Electronics Group as it leads the way in revolutionizing intermodal transportation and making a lasting impact on the industry.
Walmart To Purchase 4,500 Canoo Electric Delivery Vehicles To Be Used for Last Mile Deliveries in Support of Its Growing eCommerce Business
The retailer will be the first to receive Canoo’s Lifestyle Delivery Vehicle which is anticipated to begin hitting the road for Walmart deliveries in 2023.
July 12, 2022 8 Min. Read Innovation
Facebook
Tweet
LinkedIn
Pinterest
Email
Copied!
Last Mile Vehicle
BENTONVILLE, Ark., July 12, 2022 — Walmart (NYSE: WMT) has signed a definitive agreement with Canoo (NASDAQ: GOEV), a high-tech advanced mobility company, to purchase 4,500 all-electric delivery vehicles, beginning with the Lifestyle Delivery Vehicle (LDV), with the option to purchase up to 10,000 units. The vehicles will be used to deliver online orders in a sustainable way which will also contribute to Walmart’s goal to achieve zero-emissions by 2040. While the LDV is expected to begin hitting the road in 2023, the companies plan to kick off advanced deliveries to refine and finalize vehicle configuration in the Dallas-Fort Worth metroplex in the coming weeks.
It doesn’t matter what dude of the political fence politicians are on. They’re all corrupt and are generally motivated by who or what I directly lives their financial means. Very few are authentic “do gooders”.
Jmho!
Which isn’t worth much …
Solid 51 million in volume for a Friday…. And as slight as it was, ended up up with a green close.
Good morning! Thank you for sharing video!
Nice day! Next highest day's volume of 47mm was back on 3/17.....we're only half way through todays volumen that is already at 50mm...very nice day!
Big time as* whoopin for be too!
Me too…mad at myself for being pulled in. Stupid self!
Is the George Sharp the same guy on twitter regarding the cnna stock?
Agree!
This entire sections is concerning...standard verbiage to a degree but concerning none the less. Easy to be a bag holder....JMHO
We do not currently have sufficient cash flow to maintain our business.
We do not currently have enough cash flow to operate our business. Therefore, we will be dependent upon additional capital in the form of either debt or equity to continue our operations and expand our products to new markets. At present, we do not have arrangements to raise all of the needed additional capital, and we will need to identify potential investors and negotiate appropriate arrangements with them. We may not be able to arrange enough investment within the time the investment is required or that if it is arranged, that it will be on favorable terms. If we cannot get the needed capital, we may not be able to become profitable and may have to curtail or cease our operations.
Our management has limited experience operating a public company and is subject to the risks commonly encountered by early-stage companies.
Although our management has experience in operating small companies, our current management has not managed expansion while being a public company. Many investors may treat us as an early-stage company. Also, our management has not overseen a company with considerable growth. Because we have a limited operating history, our operating prospects should be considered in light of the risks and uncertainties frequently encountered by early-stage companies in rapidly evolving markets.
We depend heavily on key personnel.
We believe our success depends heavily on the continued active participation of our current executive officers. If we were to lose our executive officers' services, the loss could have a material adverse effect on our business, financial condition, or operation results. Also, to achieve our future growth plans, we will need to recruit, hire, train, and retain other highly qualified technical and managerial personnel. Competition for qualified employees is intense, and if we cannot attract, retain and motivate these additional employees, their absence could have a materially adverse effect on our business, financial condition, or results of operations.
Increased operating costs and obstacles to cost recovery due to the pricing and cancellation terms of our food and support services contracts may constrain our ability to make a profit.
Our profitability can be adversely affected to the extent we are faced with cost increases for supplies, raw materials, wages, other labor-related expenses, especially when we cannot recover such increased costs through increases in the prices for our products and services. In some cases, we will have to absorb any cost increases, which may adversely impact our operating results.
Governmental regulations relating to therapeutics may subject us to significant liability.
Regulations relating to therapeutics have not been fully developed. We cannot assure you that we will be able to comply with any future laws and regulations. Rules and regulations in this area may significantly increase the cost of compliance or expose us to liabilities.
If we fail to comply with applicable laws and regulations, including those referred to above, we may be subject to investigations, criminal sanctions, or civil remedies, including fines, penalties, damages, reimbursement, injunctions, seizures, or debarments from government contracts. The cost of compliance or the consequences of non-compliance, including debarments, could have a material adverse effect on our business and operations results. Also, governmental units may make changes in the regulatory frameworks within which we operate that may require either the Company as a whole or individual businesses to incur substantial increases in costs to comply with such laws and regulations.
President of FUNR is Ethan Zachadnyk from LaJolla California. His linkden profile says he's a consultant for A2z consulting....indicates Chinese and Mandarin. Not much on his profile. The other guy Graham Cox....can't find anything on him. Amazing how a company can literally create itself to trade,whether on the pinks, BB and literally be nothing more than a money scam for the persons who set it up. This is such a waste of even checking in on from time to time. Amazing all of the BS hype that was happening 12-18 months ago when it was CUBV. Such BS!
Will anything revive this turd?
When are we going to move and stay north of .10….?
Very good read
NEWS OUT!
https://mailchi.mp/ipharminc/innovation-pharma-announces-beamed-technologies-breakthrough-in-development-of-fiber-optic-probes-for-stingray-laser-system?e=2e5c4969ea>
<https://mcusercontent.com/9ed1a6b082ae8962468007971/images/09cbe22c-d172-5b20-d592-c162934f4527.png>
Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
WAKEFIELD, MA / June 5, 2023 Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to inform shareholders that BeaMed, a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovations, reported significant progress in the development of its groundbreaking StingRay Laser system (the “StingRay System”).
BeaMed has successfully completed the manufacturing of its first-ever MRI compatible fiber optic probes, marking a major technical milestone in its development of an advanced laser technology with respect to shaping energy and matching it to patient specific anatomy, a novel concept that BeaMed is proving a reality resulting in a major milestone in the advancement of the StingRay System. The completion of these probes allows for comprehensive integration tests, involving the unique MRI compatible fiber optics, an MRI interface software suite, special algorithms to simplify damage estimation, and custom insertion tools, planned to commence in late June 2023.
An initial area of emphasis of the StingRay System will be for the treatment of epilepsy. Epilepsy affects millions of people worldwide, causing recurrent seizures that significantly diminish their quality of life. Traditional treatment methods, such as medication and surgery, possess limitations and may not be effective for all patients. Recognizing the critical need for innovation, BeaMed has developed an advanced laser system designed to revolutionize epilepsy treatment.
The StingRay System, invented and developed by BeaMed, utilizes a cutting-edge laser-based thermal ablation technology specifically tailored for the treatment of previously inoperable cases of epilepsy. By employing state-of-the-art technology, this novel system precisely targets and ablates seizure-triggering brain tissues. Through controlled delivery of laser energy in a minimally invasive manner, the StingRay System offers enhanced precision and customization to address each patient's unique condition.
The StingRay System introduces entirely new designs for fiber optic probes, along with specially designed high-precision insertion tools and a new software platform for intelligent control and real-time feedback for clinicians. These innovations enable patient-specific treatments and significantly reduce navigational errors. The design and product features, including unique user interface/user experience elements, were developed in close collaboration with leading neurosurgery physicians in the US and Israel, renowned for their expertise in Laser Interstitial Thermal Therapy (LITT) procedures.
“Innovation Pharmaceuticals is delighted with the ongoing progress of BeaMed towards creating a groundbreaking product. By combining advanced technology, precision, and customization, BeaMed aims to redefine epilepsy management and provide renewed hope to patients living with this challenging condition,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals, BeaMed’s lead investor. “With BeaMed management's proven track record in developing and commercializing surgical laser technologies, we anticipate that the StingRay System will achieve similar success.”
“BeaMed is committed to bringing to market the best possible surgical solution for treating drug resistant epilepsy. Focused and in-depth discussions, alongside intimate involvement of the world’s top clinicians, has allowed us to match the StingRay product architecture to the most advanced surgical needs and requirements. We are excited about BeaMed’s transformational path ahead,” said Gil Shapira, co-founder of BeaMed.
BeaMed was founded by Moshe Eshkol and Gil Shapira, both highly experienced specialists in surgical lasers and medical devices. BeaMed and the development of the StingRay System are also supported by a special prestigious grant from the BIRD Foundation (https://www.birdf.com/), a bi-national organization supporting Israel-US collaboration. Gil Shapira brings forward 28 years of engineering and product development and management experience, with over 19 years in the surgical laser industry. Gil owns and manages neoLaser, a company he founded in 2012, and led to revenue growth and profitability, with a 43% CAGR on its way to more than 1500 global installations and performing 70,000+ surgeries annually in over 30 countries. Previously, Gil led product development and marketing at OmniGuide, a successful high-growth laser based medical device spin-off out of the Massachusetts Institute of Technology (MIT).
Thank you for the insight urock…. appreciate it! The phone number I dialed was a 302 area code.
JC…..Is their profile information, website and phone number correct? I tried looking at their website and phoning corporate. The website doesn’t work, nor does anyone answer the phone.
What is your by zone?
Tuesday morning…WTF?
Especially if it’s parabolic.